← Every product built on public research
Progeria Research Foundation/Elger Biopharmaceuticals · Lonafarnib
Zokinvy: invented in a government lab
–
Medicare paid, 2025
before rebates
–
Medicare, 2020–2025
–
Medicare, 2026 Q1
the newest quarter CMS has published
$4.4M
Medicaid paid, 2024
before rebates
The public record, link by link
1 · Public research
Invented in NIH labs and licensed to Progeria Research Foundation/Elger Biopharmaceuticals.2 · Patent
Patents 7838531, 8257915, 8691501, 8828356, licensed by NIH.3 · FDA approval
Approved Nov 20, 2020, sold by Progeria Research Foundation/Elger Biopharmaceuticals (NDA 213969); orphan-drug exclusivity runs to Nov 20, 2027.4 · Public pays
Medicaid paid $4.4M in 2024. Medicare's 2025 drug files do not list it.
The government license
NIH to Progeria Research Foundation/Elger Biopharmaceuticals
Zokinsky (lonafarnib) is a farnesyltransferase inhibitor that helps prevent the buildup of defective progerin or progerin-like protein of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL). Hutchinson-Gilford and progeroid laminopathies are two distinct fatal diseases marked by premature aging.
First sold 2021. Licensed patents: US 7838531, US 8257915, US 8691501, US 8828356. See the list
Progeria Research Foundation/Elger Biopharmaceuticals's side
Drug makers pay for the clinical trials that take a compound from the lab to FDA approval, and they pay royalties on licensed patents. Those terms are not public. Progeria Research Foundation/Elger Biopharmaceuticals's page shows its other products on this list, its federal awards, its PAC's giving and its lobbying. If Progeria Research Foundation/Elger Biopharmaceuticals wants to add its account, we will publish it here.
How this is built. A product is listed for one of two public records. Either NIH's Technology Transfer office lists it as an FDA-approved product built on a license from an NIH, CDC or FDA lab, or a patent the FDA lists for the drug was reported to NIH as an invention made with NIH grant money, as the Bayh-Dole Act requires. We then add what Medicare Part D, Part B and Medicaid paid for each product, and for each company, the federal grants and contracts it received, its PAC's donations and its lobbying.
What the numbers mean. Medicare and Medicaid figures are gross spending before the rebates drug makers pay back, which are confidential. Hospital-administered therapies such as CAR-T cell treatments are mostly paid under Medicare Part A and do not appear in these files. "NIH grants" is everything NIH paid on the grants a patent was reported under, from 1985 on; a grant usually paid for more than one invention, so it is not the cost of the drug. Federal contracts include purchases, such as vaccine doses, as well as research. Companies also paid for the clinical trials that took these products to approval. None of these figures shows that public money set a price or bought a decision.
Sources: NIH Technology Transfer: FDA-approved products licensed from NIH, CDC and FDA labs; NIH RePORTER patents reported under NIH grants (from iEdison); NIH RePORTER project funding; FDA Orange Book patent, exclusivity and product files; CMS Medicare Part D and Part B Spending by Drug (annual and quarterly); CMS Medicaid Spending by Drug; USAspending.gov federal grants and contracts. Updated 2026-11-06.